Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Authors:
Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M and Hodgson R.
Publication type:
Journal article
Publication name:
Pharmacoeconomics
Citation:
Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M and Hodgson R. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017.
